Fig. 4

DOX@3D-MPs-induced enhanced antitumor immunity in H22 and 4T1 tumor-bearing mice. a Schematic timeline for tumor immune microenvironment analysis in H22 and 4T1 tumor-bearing mice after administration of six doses of PBS, 3D-MPs, DOX, 3D-MPs+DOX, DOX@3D-MPs derived from H22 TRCs and 4T1 TRCs at DOX dosage of 0.75 mg kg⁻¹ once every other day, respectively, or three doses of high dosage of Doxil at 4 mg kg⁻¹ once every 3 days via tail vein. b–j Numbers of CD11c⁺CD80⁺CD86⁺ (b), CD11c⁺MHC-II⁺ (c), CD8⁺ T (d), CD8⁺Ki67⁺ T (e), CD8⁺CD69⁺ T (f), CD8⁺IL-2⁺ T (g), CD8⁺IFN-γ⁺ T (h), CD8⁺TNF-α⁺ T (i), and CD8⁺GzmB⁺ T (j) cells in tumor tissues of H22 tumor-bearing mice at 11 days after treatments indicated in a. (n = 6 mice in each group). k, l Numbers of CD8⁺CD44⁺CD62L⁺ T (k) and CD8⁺CD44⁺CD62L^- T cells (l) in the spleens of H22 tumor-bearing mice at 11 days after treatments indicated in (a). (n = 6 mice in each group). m Relative numbers of CD11c⁺CD80⁺CD86⁺, CD11c⁺MHC-II⁺, CD8⁺ T, CD8⁺Ki67⁺ T, CD8⁺CD69⁺ T, CD8⁺IFN-γ⁺ T and CD8⁺GzmB⁺ T cells in tumor tissues, and CD8⁺CD44⁺CD62L⁺ T and CD8⁺CD44⁺CD62L^- T cells in the spleens of orthotopic 4T1 tumor-bearing mice at 11 days after treatments indicated in (a). (n = 6 mice in each group). n, o Representative images (n) and numbers (o) of IFN-γ immune spots from 4T1 cell debris-restimulated splenocytes isolated from orthotopic 4T1 tumor-bearing mice after treatments indicated in (a) by ELISpot assay. (n = 6 mice in each group). p Cytotoxicity of T cells (effector cells) against 4T1 cells (target cells) at 24 h after T cells isolated from 4T1 cell debris-restimulated splenocytes of orthotopic 4T1 tumor-bearing mice treated as indicated in a were incubated with 4T1 cells at different effector/target ratios by LDH assay. (n = 3). Data are shown as means ± s.d. *P < 0.05, **P < 0.01, ***P < 0.001